OMERS ADMINISTRATION Corp Purchases New Shares in Medpace Holdings, Inc. $MEDP

OMERS ADMINISTRATION Corp acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 4,030 shares of the company’s stock, valued at approximately $2,134,000.

Several other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Medpace during the second quarter worth $1,323,047,000. AQR Capital Management LLC grew its stake in shares of Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after acquiring an additional 404,226 shares in the last quarter. Madison Asset Management LLC bought a new position in Medpace during the second quarter worth about $128,956,000. Arrowstreet Capital Limited Partnership increased its position in Medpace by 205.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after acquiring an additional 211,411 shares during the period. Finally, Franklin Resources Inc. increased its position in Medpace by 158.6% during the fourth quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock worth $168,198,000 after acquiring an additional 183,645 shares during the period. Institutional investors own 77.98% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on MEDP. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Mizuho raised their target price on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Robert W. Baird lifted their price target on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. TD Cowen boosted their price target on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Finally, BMO Capital Markets increased their price target on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $584.18.

Medpace Stock Up 0.8%

Shares of Medpace stock opened at $619.05 on Thursday. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90. The company has a market capitalization of $17.28 billion, a price-to-earnings ratio of 36.29, a PEG ratio of 2.74 and a beta of 1.15. The firm’s 50-day moving average price is $559.49 and its two-hundred day moving average price is $493.31.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same period in the previous year, the company earned $3.10 EPS. The business’s revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Insider Activity

In other news, CEO August J. Troendle sold 27,174 shares of Medpace stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $618.79, for a total value of $16,814,999.46. Following the transaction, the chief executive officer owned 561,195 shares in the company, valued at approximately $347,261,854.05. This trade represents a 4.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Brian T. Carley sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total value of $3,043,150.00. Following the transaction, the director directly owned 27,825 shares of the company’s stock, valued at $16,935,129.75. This trade represents a 15.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 125,290 shares of company stock valued at $76,466,988 in the last three months. Company insiders own 20.50% of the company’s stock.

Medpace News Summary

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace remains near a potential technical buy point of $628.92 after its July advance. The stock is trading well above its 50-day and 200-day moving averages, indicating sustained momentum. Medpace Stock Hovers Near Entry, Offers Second Chance After July Spike
• Positive Sentiment: The company’s latest quarterly results exceeded expectations: adjusted earnings were $4.25 per share versus the $3.98 consensus estimate, while revenue rose 17.2% year over year to $707.33 million, surpassing forecasts. Fiscal 2026 EPS guidance remains $17.25 to $17.95.
• Positive Sentiment: Institutional investors and hedge funds own approximately 78% of Medpace, and several investment firms have recently increased their positions. Some analysts have also raised price targets, including RBC’s $692 target and Mizuho’s $665 target.
• Neutral Sentiment: Value-focused investors are comparing Medpace with Concentra Group, but the available report does not establish a clear valuation advantage for MEDP. The stock trades at roughly 36 times earnings, with a PEG ratio above 2.7, suggesting investors are already paying a premium for growth. CON vs. MEDP: Which Stock Should Value Investors Buy Now?
• Neutral Sentiment: Reported short interest was zero shares, producing a zero-day days-to-cover ratio. This provides no meaningful evidence of short-covering demand or downside pressure.
• Negative Sentiment: Several executives have recently sold shares near $620–$625. CEO August Troendle sold 15,978 shares in two transactions worth approximately $9.97 million, while CFO Kevin Brady sold 3,400 shares valued at about $2.13 million. Although both executives retain shares, the concentration of insider selling could weigh on sentiment. Medpace CEO August Troendle Sells 1,983 Shares
• Negative Sentiment: Analyst opinion remains cautious overall: the consensus rating is “Hold,” and the average price target of $584.18 is below recent trading levels. This may make additional upside more difficult without another earnings or guidance catalyst.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.